COO: The Cooper Companies, Inc. Price to Sales

Material innovations and physician support create a robust defensive barrier for The Cooper Companies (COO). The cost-to-sales ratio visualizes this resilience, with 2.80 serving as the current metric level. Stability is driven by leadership in the lenses and women's health segments. An oligopolistic status and strict prescription requirements allow the company to confidently exercise pricing power.

To minimize fundamental risks, investors should utilize the market capitalization-to-annual revenue ratio, which determines the cost of one dollar of sales and identifies asset overvaluation. For The Cooper Companies (COO), which invests in a staff of unique specialists and innovation, the P/S ratio chart allows for an assessment of the extent to which the market is willing to award a premium for the high cost of medical equipment development relative to current sales volumes.